small molecule

HYFTOR

SIROLIMUS

Loss of exclusivityMarch 2029FDA regulatory exclusivity expiry

CompanyNobelpharma →See this company's full patent-cliff portfolio

Drug detail

Brand name	HYFTOR
Active ingredient	SIROLIMUS
Strength	0.2%
Dosage form	GEL
Route	TOPICAL
Modality	Small molecule
FDA approval	March 2022
Marketing status	RX

Regulatory exclusivity

Code	Expires
ODE-391	March 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.